BioXcel Therapeutics Files 2024 10-K
Ticker: BTAI · Form: 10-K · Filed: Mar 28, 2025 · CIK: 1720893
Sentiment: neutral
Topics: 10-K, financials, offering
Related Tickers: BTAI
TL;DR
BTAI 2024 10-K filed. Key events: March 2024 RDO, Feb 2025 purchase agreement.
AI Summary
BioXcel Therapeutics, Inc. filed its 2024 10-K on March 28, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company is involved in the pharmaceutical preparations industry, with its principal executive offices located in New Haven, CT. Key financial events include a registered direct offering on March 25, 2024, and a subsequent event on February 10, 2025, related to a purchase agreement for registered securities.
Why It Matters
This filing provides investors with a comprehensive overview of BioXcel Therapeutics' financial health and operational activities for the past fiscal year, including significant capital-raising events.
Risk Assessment
Risk Level: medium — The company's financial activities, including registered direct offerings and purchase agreements, suggest potential dilution or financing needs, which can be a risk for investors.
Key Numbers
- 1871000 — OtherNonoperatingIncomeExpense (Reported value for Other Nonoperating Income Expense)
- 3102000 — OtherNonoperatingIncomeExpense (Reported value for Other Nonoperating Income Expense)
Key Players & Entities
- BioXcel Therapeutics, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-28 (date) — Filing date
- New Haven, CT (location) — Business and mail address
- 203-643-8060 (phone_number) — Business phone number
- 2024-03-25 (date) — Registered Direct Offering date
- 2025-02-10 (date) — Subsequent event date (Purchase Agreement)
FAQ
What was the total revenue for BioXcel Therapeutics in the fiscal year ending December 31, 2024?
The provided text does not contain specific total revenue figures for the fiscal year ending December 31, 2024.
What is the primary business of BioXcel Therapeutics, Inc.?
BioXcel Therapeutics, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
When did BioXcel Therapeutics conduct a registered direct offering?
BioXcel Therapeutics conducted a registered direct offering on March 25, 2024.
What significant subsequent event occurred on February 10, 2025?
On February 10, 2025, there was a subsequent event related to a Purchase Agreement for Registered Securities.
Where are BioXcel Therapeutics' principal executive offices located?
BioXcel Therapeutics' principal executive offices are located at 555 Long Wharf Drive, New Haven, CT 06511.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 28, 2025 regarding BioXcel Therapeutics, Inc. (BTAI).